Abstract:Traditional High-Throughput Screening (HTS) drug discovery is inefficient. Hit rates for compounds with clinical therapeutic potential are typically 0.5% and only up to 2% maximally. Deep learning models have enriched screening rates to 28%; however, these results include hits with non-therapeutic relevant concentrations, insufficient novelty to their training set, and traverse limited chemical space. This study introduces a novel artificial intelligence (AI)-driven platform, GALILEO, and the Molecular-Geometric Deep Learning (Mol-GDL) model, ChemPrint. This model deploys both t-distributed Stochastic Neighbor Embedding (t-SNE) data splitting to maximize chemical dissimilarity during training and adaptive molecular embeddings to enhance predictive capabilities and navigate uncharted molecular territories. When tested retrospectively, ChemPrint outperformed a panel of five models for the difficult-to-drug oncology targets, AXL and BRD4, achieving an average AUROC score of 0.897 for AXL and 0.876 for BRD4 using the t-SNE split, compared to benchmark model scores ranging from 0.826 to 0.885 for AXL and 0.801 to 0.852 for BRD4. In a zero-shot prospective study, in vitro testing demonstrated that 19 of 41 compounds nominated by ChemPrint against AXL and BRD4 demonstrated inhibitory activity at concentrations ≤ 20μM, a 46% hit rate. The 19 hits reported an average-maximum Tanimoto similarity score of 0.36 relative to their training set and scores of 0.13 (AXL) and 0.10 (BRD4) relative to clinical stage compounds for these targets. Our findings demonstrate that increasing test set difficulty through training and testing ChemPrint on datasets with maximal dissimilarity enhances the predictive capabilities of the model. This results in the discovery of compound libraries at high hit rates with low therapeutic concentrations and high chemical novelty. Taken together, the proposed platform sets a new performance standard.

BioPrint meets the AI age: development of artificial intelligence-based ADMET models for the drug discovery platform SAFIRE

ChemPrint: An AI-Driven Framework for Enhanced Drug Discovery

ADMET-AI: a machine learning ADMET platform for evaluation of large-scale chemical libraries

admetSAR3.0: a comprehensive platform for exploration, prediction and optimization of chemical ADMET properties

In Silico Admet Prediction : Recent Advances, Current Challenges and Future Trends

The Trends and Future Prospective of In Silico Models from the Viewpoint of ADME Evaluation in Drug Discovery

FP-ADMET: a compendium of fingerprint-based ADMET prediction models

admetSAR: A Comprehensive Source and Free Tool for Assessment of Chemical ADMET Properties

ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties

ADMETlab: a Platform for Systematic ADMET Evaluation Based on a Comprehensively Collected ADMET Database

Interpretable-ADMET: a web service for ADMET prediction and optimization based on deep neural representation

Artificial intelligence and cheminformatics tools: a contribution to the drug development and chemical science

SmartCADD: AI-QM Empowered Drug Discovery Platform with Explainability

Validating ADME QSAR Models Using Marketed Drugs

SwissADME and pkCSM Webservers Predictors: an integrated Online Platform for Accurate and Comprehensive Predictions for In Silico ADME/T Properties of Artemisinin and its Derivatives

M3DISEEN: A novel machine learning approach for predicting the 3D printability of medicines

Pharmacoprint -- a combination of pharmacophore fingerprint and artificial intelligence as a tool for computer-aided drug design

ADMET-score - a comprehensive scoring function for evaluation of chemical drug-likeness.

Bench to bedside: The ambitious goal of transducing medicinal chemistry from the lab to the clinic

Predicting ADME properties in silico: methods and models